Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial

Authors

Institutions

Publication Details

Journal
Infectious Diseases and Therapy
Published
2025-10-14
DOI
https://doi.org/10.1007/s40121-025-01228-w
Citations
1
Primary Topic
Long-Term Effects of COVID-19
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial

Elena Tudone, Paul Cislo, Ruth Mokgokong, Joseph C. Cappelleri et al.
1 citations
Infectious Diseases and Therapy
Long-Term Effects of COVID-19
1.39
article

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial

Elena Tudone, Paul Cislo, Ruth Mokgokong, Joseph C. Cappelleri, Edward A. Weinstein
article en
1 citations

Abstract

No abstract available for this paper.
Infectious Diseases and TherapyVol. 14(12)
Pfizer (United States) (US), Pfizer (United Kingdom) (GB), Pfizer (Italy) (IT)
Openalex Percentile: Top 15%
Long-Term Effects of COVID-19
1.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.